Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two week high of $33.33. The company has a market capitalization of $3.06 billion, a P/E ratio of -7.70 and a beta of 1.39.

And Denali (Nasdaq: DNLI ... Earlier this week, its experimental drug for amyotrophic lateral sclerosis, DNL-343, failed a Phase II/III study at Massachusetts General Hospital, and on Wednesday ...

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.

Denali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, tividenofusp alfa (DNL310), for the treatment of individuals with ...

NEW YORK, NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that it has deposited into the Company’s trust account ...

On Wednesday, Stifel analysts maintained a Buy rating on shares of Denali Therapeutics Inc. (NASDAQ:DNLI) with a price target of $37.00. According to InvestingPro data, analysts remain highly bullish ...

SOUTH SAN FRANCISCO - Denali Therapeutics Inc. (NASDAQ: NASDAQ:DNLI), a biopharmaceutical company currently valued at $3.05 billion and trading below its InvestingPro Fair Value, announced today that ...

On Wednesday, Stifel analysts maintained a Buy rating on shares of Denali Therapeutics Inc. (NASDAQ:DNLI) with a price target of $37.00. According to InvestingPro data, analysts remain highly ...

According to a press release from Denali Therapeutics Inc., the small molecule DNL343 was examined in the Healey ALS Platform study, whose primary endpoint was change in disease severity measured ...